U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma
- 10 September 2012
- journal article
- review article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 168 (1), 192-200
- https://doi.org/10.1111/bjd.12042
Abstract
Background Bexarotene is a synthetic retinoid from the subclass of retinoids called rexinoids which selectively activate retinoid X receptors. It has activity in cutaneous T‐cell lymphoma (CTCL) and has been approved by the European Medicines Agency since 1999 for treatment of the skin manifestations of advanced‐stage (IIB–IVB) CTCL in adult patients refractory to at least one systemic treatment. In vivo bexarotene produces primary hypothyroidism which may be managed with thyroxine replacement. It also affects lipid metabolism, typically resulting in raised triglycerides, which requires prophylactic lipid‐modification therapy. Effects on neutrophils, glucose and liver function may also occur. These side‐effects are dose dependent and may be controlled with corrective therapy or dose adjustments. Objectives To produce a U.K. statement outlining a bexarotene dosing schedule and monitoring protocol to enable bexarotene prescribers to deliver bexarotene safely for optimal effect. Methods Leaders from U.K. supraregional centres produced this consensus statement after a series of meetings and a review of the literature. Results The statement outlines a bexarotene dosing schedule and monitoring protocol. This gives instructions on monitoring and treating thyroid, lipid, liver, blood count, creatine kinase, glucose and amylase abnormalities. The statement also includes algorithms for a bexarotene protocol and lipid management, which may be used in the clinical setting. Conclusion Clinical prescribing of bexarotene for patients with CTCL requires careful monitoring to allow safe administration of bexarotene at the optimal dose.Keywords
This publication has 36 references indexed in Scilit:
- Bexarotene therapy for mycosis fungoides and Sézary syndromeBritish Journal of Dermatology, 2009
- Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphomaBritish Journal of Dermatology, 2009
- Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphomaJournal of Dermatological Treatment, 2009
- The optimal use of bexarotene in cutaneous T-cell lymphomaBritish Journal of Dermatology, 2007
- Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and Sézary syndromeBritish Journal of Dermatology, 2007
- Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa‐2b (Intron‐A) for patients with cutaneous T‐cell lymphomaCancer, 2007
- Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinionBritish Journal of Dermatology, 2006
- Treatment of Mycosis Fungoides with Denileukin Diftitox and Oral BexaroteneClinical Lymphoma Myeloma and Leukemia, 2006
- JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practiceHeart, 2005
- Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanismsJournal of the American Academy of Dermatology, 2004